Powered by: Motilal Oswal
2026-03-20 12:35:53 pm | Source: Accord Fintech
Tata Elxsi zooms on launching 'Terumo - Tata Elxsi Offshore Development Center' with Terumo Corporation
Tata Elxsi zooms on launching 'Terumo - Tata Elxsi Offshore Development Center' with Terumo Corporation

Tata Elxsi is currently trading at Rs. 4203.75, up by 165.65 points or 4.10% from its previous closing of Rs. 4038.10 on the BSE.

The scrip opened at Rs. 4153.25 and has touched a high and low of Rs. 4276.80 and Rs. 4106.40 respectively. So far 18444 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 6733.50 on 10-Jun-2025 and a 52 week low of Rs. 4023.00 on 19-Mar-2026.

Last one week high and low of the scrip stood at Rs. 4321.50 and Rs. 4023.00 respectively. The current market cap of the company is Rs. 26401.33 crore.

The promoters holding in the company stood at 43.90%, while Institutions and Non-Institutions held 20.86% and 35.24% respectively.

Tata Elxsi and Terumo Corporation, a global medical innovation company, have launched the ‘Terumo - Tata Elxsi Offshore Development Center’. This dedicated center will support the development of Terumo’s cardiac and vascular solutions, strengthening engineering and innovation capabilities while enabling continuous lifecycle support across international markets. The center brings together multidisciplinary teams, with the company’s expertise in design, engineering, verification, regulatory compliance, and localisation, along with the thoughtful application of AI, GenAI, and digital capabilities in software engineering. This enables faster development and regional adaptation while addressing the growing demand for patient-centric medical devices with improved cost efficiency and product differentiation.

The collaboration advances the reliability and performance of cardiac and vascular technologies, supporting their global availability and helping ensure they meet industry standards and the evolving needs of healthcare providers and patients.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here